BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 30126402)

  • 1. Changes in the outcome of prostate biopsies after preventive task force recommendation against prostate-specific antigen screening.
    Zakaria AS; Dragomir A; Brimo F; Kassouf W; Tanguay S; Aprikian A
    BMC Urol; 2018 Aug; 18(1):69. PubMed ID: 30126402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate Needle Biopsy Outcomes in the Era of the U.S. Preventive Services Task Force Recommendation against Prostate Specific Antigen Based Screening.
    Banerji JS; Wolff EM; Massman JD; Odem-Davis K; Porter CR; Corman JM
    J Urol; 2016 Jan; 195(1):66-73. PubMed ID: 26254722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. US Preventive Services Task Force prostate-specific antigen screening guidelines result in higher Gleason score diagnoses.
    Gejerman G; Ciccone P; Goldstein M; Lanteri V; Schlecker B; Sanzone J; Esposito M; Rome S; Ciccone M; Margolis E; Simon R; Guo Y; Pentakota SR; Sadeghi-Nejad H
    Investig Clin Urol; 2017 Nov; 58(6):423-428. PubMed ID: 29124241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Change in prostate cancer presentation coinciding with USPSTF screening recommendations at a community-based urology practice.
    Gaylis FD; Choi JE; Hamilton Z; Dato P; Cohen E; Calabrese R; Prime H; Rosenbaum A; Kader AK
    Urol Oncol; 2017 Nov; 35(11):663.e1-663.e7. PubMed ID: 28736250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of the U.S. Preventive Services Task Force recommendations against prostate specific antigen screening on prostate biopsy and cancer detection rates.
    Bhindi B; Mamdani M; Kulkarni GS; Finelli A; Hamilton RJ; Trachtenberg J; Zlotta AR; Evans A; van der Kwast TH; Toi A; Fleshner NE
    J Urol; 2015 May; 193(5):1519-24. PubMed ID: 25481037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes observed in prostate biopsy practices in an inner city hospital with a high risk patient population following the 2012 uspstf psa screening recommendations.
    Tam AW; Khusid J; Inoyatov I; Becerra AZ; Davila J; Chouhan JD; Weiss JP; Hyacinthe LM; McNeil BK; Winer AG
    Int Braz J Urol; 2018; 44(4):697-703. PubMed ID: 29617073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate Biopsy Features: A Comparison Between the Pre- and Post-2012 United States Preventive Services Task Force Prostate Cancer Screening Guidelines With Emphasis on African American and Septuagenarian Men.
    Shah N; Ioffe V; Cherone S
    Rev Urol; 2019; 21(1):1-7. PubMed ID: 31239823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
    Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
    BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
    Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
    BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States.
    Kelly SP; Anderson WF; Rosenberg PS; Cook MB
    Eur Urol Focus; 2018 Jan; 4(1):121-127. PubMed ID: 29162421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications.
    Gershman B; Van Houten HK; Herrin J; Moreira DM; Kim SP; Shah ND; Karnes RJ
    Eur Urol; 2017 Jan; 71(1):55-65. PubMed ID: 26995328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testing and referral patterns in the years surrounding the US Preventive Services Task Force recommendation against prostate-specific antigen screening.
    Hutchinson R; Akhtar A; Haridas J; Bhat D; Roehrborn C; Lotan Y
    Cancer; 2016 Dec; 122(24):3785-3793. PubMed ID: 27658175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metastatic prostate cancer incidence in Australia after amendment to prostate-specific antigen screening guidelines.
    Smith S; Wolanski P
    ANZ J Surg; 2018; 88(7-8):E589-E593. PubMed ID: 29194902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer screening in Tyrol, Austria: experience and results.
    Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
    Eur Urol; 1999; 35(5-6):523-38. PubMed ID: 10325519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the 2012 and 2018 US preventive services task force prostate cancer screening guidelines on pathologic outcomes after prostatectomy.
    Plambeck BD; Wang LL; Mcgirr S; Jiang J; Van Leeuwen BJ; Lagrange CA; Boyle SL
    Prostate; 2022 Feb; 82(2):216-220. PubMed ID: 34807485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the 2012 United States Preventive Services Task Force statement on prostate-specific antigen screening: analysis of urologic and primary care practices.
    Perez TY; Danzig MR; Ghandour RA; Badani KK; Benson MC; McKiernan JM
    Urology; 2015 Jan; 85(1):85-9. PubMed ID: 25440819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increasing aggressive prostate cancer.
    Shah N; Ioffe V; Chang JC
    Can J Urol; 2022 Dec; 29(6):11384-11390. PubMed ID: 36495581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the USPSTF Grade D Recommendation against Screening for Prostate Cancer on Incident Prostate Cancer Diagnoses in the United States.
    Barocas DA; Mallin K; Graves AJ; Penson DF; Palis B; Winchester DP; Chang SS
    J Urol; 2015 Dec; 194(6):1587-93. PubMed ID: 26087383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secular Trends in Prostate Biopsy Criteria and Outcomes: The Dartmouth Experience.
    Reinstatler L; Rissman C; Seigne JD; Hyams ES
    Urology; 2017 Sep; 107():178-183. PubMed ID: 28595934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4-10 ng/ml?
    Xu N; Wu YP; Chen DN; Ke ZB; Cai H; Wei Y; Zheng QS; Huang JB; Li XD; Xue XY
    J Cancer Res Clin Oncol; 2018 May; 144(5):987-995. PubMed ID: 29504080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.